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Vaccine efficacy in aquaculture has for a long time depended on evaluating relative percent survival and antibody responses after
vaccination. However, current advances in vaccine immunology show that the route in which antigens are delivered into cells is
deterministic of the type of adaptive immune response evoked by vaccination. Antigens delivered by the intracellular route induce
MHC-I restricted CD8+ responses while antigens presented through the extracellular route activate MHC-II restricted CD4+
responses implying that the route of antigen delivery is a conduit to induction of B- or T-cell immune responses. In finfish, different
antigen delivery systems have been explored that include live, DNA, inactivated whole virus, fusion protein, virus-like particles,
and subunit vaccines although mechanisms linking these delivery systems to protective immunity have not been studied in detail.
Hence, in this review we provide a synopsis of different strategies used to administer viral antigens via the intra- or extracellular
compartments. Further, we highlight the differences in immune responses induced by antigens processed by the endogenous route
compared to exogenously processed antigens. Overall, we anticipate that the synopsis put together in this review will shed insights
into limitations and successes of the current vaccination strategies used in finfish vaccinology.
1. Introduction
The central hallmark of vaccination is to prime the adaptive
immune system to develop immune responses that will
protect the host organism upon a second encounter with
the same pathogen. However, priming the adaptive immune
system requires activation of naı¨ve B- andT-lymphocytes into
effector cells that translate into protective immunity. While
studies on the immunological basis of vaccine protection have
for a long time focused on humoral and cellular responses
as measures of protective immunity, growing evidence shows
that the mode by which antigens are presented to B- or T-
lymphocytes has a significant influence on the outcome of
adaptive immune responses induced by vaccination which is
also influenced by the mode in which antigens are adminis-
tered to host cells [1, 2]. Put together, these elements drive
vaccine development into a cross-talk between vaccinology
and immunology in which vaccine design and its delivery
(vaccinology) on one hand have to be optimized in order
to gain an effective immune response (immunology) on
the other. Hence, optimization of antigen design and its
delivery into host cells is a prerequisite to inducing an optimal
protective immune response.
Unlike B-lymphocytes, which are precursors of antibody
secreting cells that can recognize antigens through primed
antigen presenting cells (APCs)/activated B-cells [1], T-cell
receptors (TCRs) can only “see” antigens that are processed
and presented by APCs. TCRs recognize antigen peptides
bound on the surface of MHC molecules [2]. Endogenous
peptides derived from intracellular sources such as repli-
cating virus are synthesized and processed for presentation
to naı¨ve CD8 T-cells by MHC-I molecules while exogenous
peptides derived from extracellular sources are processed
and presented to naı¨ve CD4 T-cells by MHC-II molecules.
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An alternative mechanism that permits some extracellular
antigens to activate na¨ıve CD8 T-cells called cross presen-
tation exists which occurs via the MHC-I pathway [3, 4].
For antigens delivered via the endosomal route, proteosomes
degrade soluble antigens after ubiquitination which have
been synthesized in the cytosol or escaped to the endoplasmic
reticulum (ER) by cross presentation [5]. Thereafter, the
processed antigens are released after proteosomal degra-
dation to generate peptides that are transported into the
ER by the transporter-associated antigen processing (TAPs)
[5, 6]. Once in the ER, the antigenic peptides are loaded
onto MHC-I molecules for presentation on the cell surface
where they initiate the activation of na¨ıve CD8 T-cells into
effector cytotoxic T-lymphocytes (CTLs) [7–9]. In the case
of antigens delivered by the exogenous route, lysosomes
degrade endocytosed antigens after endosomal fusion with
lysosomes [10]. In general, lysosomes can degrade complex
structures such as whole viral particles that are delivered
to them via endocytosis by the extracellular route [11]. Pre-
sentation of processed peptides by endosomal degradation
leads to maturation of APCs into professional APCs which is
characterized by expressing MHC-II molecules and antigen
specific signaling molecules such CD40L, CD80, and CD86.
The resulting professional APCs are the prime initiators
of adaptive immune responses that activate na¨ıve T-cells
into effector cells through the MHC-peptide complexes and
immunemodulationmolecules.Therefore, it follows that, for
a vaccine antigen to turn naı¨ve B- or T-lymphocytes into
“protective” cell, there has to be an efficient antigen delivery
system that stimulates the activation of cell of the adaptive
immune system.
Although studies on antigen presentation in fish
immunology have gained prominence in recent years [12–14],
there is still limited research on activation of cells of the
adaptive immune system by APCs, which precludes our
understanding of the role of innate immunity in optimizing
vaccine performance. Despite that, several studies have been
carried out trying to deliver viral antigens into different
compartments of fish cells. Hence, in this review we provide
an overview of these delivery systems and based on this
approach we highlight the different immune responses
induced by antigens delivered by the intracellular route
compared to antigens delivered by the extracellular route. In
addition, we also highlight the differences in vaccine
efficacy from fish immunized using antigens delivered by
the exogenous route compared to fish vaccinated using the
endogenous route. Overall, we anticipate that the synopsis of
different antigen delivery systems put together in this review
will shed new insights into limitations and successes of the
current vaccination strategies used in fish vaccinology.
2. Fish Antigen Presenting Cells, Adaptive
Immune Cells, and Their Receptors
In mammals, antigen presentation is carried out by differ-
ent cell types that include monocytes, macrophages, and
dendritic cells [15]. These cells possess pattern recognition
receptors (PRRs) that recognize and bind to pathogen associ-
ated molecular patterns (PAMPs) known as “danger signals”
on pathogens [16]. Upon binding to PAMPs using PRRs,
monocytes mature into macrophages while immature den-
dritic cells (DCs) also transform into mature dendritic ones
to become professional APCs, which induce the expression
of proinflammatory cytokines that attract more APCs to
the sites of antigen deposition [15, 17]. Upon encounter
with the APCs, na¨ıve B- and T-cells undergo maturation to
become memory cells capable of recognizing the antigens in
subsequent encounters thereby creating the basis acquired
immunity.
In teleosts fish, APCs known to possess PRRs having the
capacity to bind to different PAMPs on pathogens have been
described in different species and these include monocytes,
macrophages, and dendritic-like cells [13, 18–26]. In addition
fish B-cells have been shown to carry out antigen presentation
apart from their role as antibody secreting cells [27]. As
a result, in vitro methods for culturing fish monocytes,
macrophages, and dendritic-like cells have been developed
which makes it easy to study antigen presentation using cell
cultures [18, 19, 24, 25]. It is interesting to note that TAP genes
comparable to those seen in mammals have been identified
and mapped to MHC regions in different cartilaginous and
bony fish species suggesting that similar mechanisms of
endogenous antigen processing seen in higher vertebrates
also exist in teleosts fish [28–31]. Unlike in mammals where
APCs carrying processed antigens migrate to the lymph
nodes [32], in fish APCs carrying antigens migrate to the
head, kidney, and spleen [13], which are the major lymphoid
organs [33]. Apart from lymphoid organs, APCs have been
detected in other organs such as the gills, skin, and intestines
in fish [34, 35]. In addition, different phagocytic cell types
have been characterized in fish although their antigen pre-
sentation capabilities have not been investigated [36, 37].
Similar to their mammalian counterparts, fish APCs
possess a wide range of surface markers that include
CD80/CD86, CD83, CD209, MHC-I, and MHC-II proteins
[20, 38–41]. In fish, CD83 has been shown to be an activa-
tion marker for macrophages [42] and dendritic-like cells
[23]. Apart from CD83, other surface markers identified
for fish dendritic-like cells include CD208/lysosomal associ-
ated membrane protein (LAMP3) [43]. Recently, Zhu et al.
[44] showed that fish B-cells act as pivotal APCs in priming
the adaptive immune system using CD80/CD86 molecules.
In another study, Abo´s et al. [45] showed upregulation
of MHC-II genes that coincided with upregulation of
CD80/CD86 genes in a nonlethal infection (no cytopathic
effects observed) of viral hemorrhagic septicemia virus
(VHSV) in IgM+ cells which consolidates the notion that fish
B-cells use CD80/CD86 molecules to activate the adaptive
immune system using the MHC-II pathway [44, 46].
As shown in Table 1, all four T-cell receptor chains (𝛼,
𝛽, 𝛾, and 𝛿) required for binding to APCs together with the
four chains (𝛾-, 𝛿-, 𝜀-, and 𝜁-chain) of the CD3 coreceptor
complex required for T-cell activation in mammals have
been reported in fish. In addition, the T-cell costimulatory
marker CD28 and the negative regulatory marker CTLA-4,
which bind to CD80 and CD86 receptors on APCs, have
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Table 1: Fish antigen presenting and adaptive immunity cell receptors.
Protein Selected examples of fish species Reference
(1) Antigen presenting surface markers and MHCmolecules
CD80 (B7.1) Zebrafish, rainbow trout [44, 159]
CD83 (7.2) Zebrafish, turbot, Atlantic salmon [44, 159–161]
CD86 Zebrafish, rainbow trout [44, 159]
CD209 Zebrafish [162]
MHC-I Orange spotted grouper, sea bass, grass carp [49, 163, 164]
MHC-II Zebrafish, lake trout, [159, 165]
(2) T-cell receptors, costimulatory and activator molecules
CD3𝛾 Atlantic salmon [166]
CD3𝜀 Atlantic salmon [166]
CD3𝜁 Atlantic salmon [166, 167]
CD3𝛿 Rainbow trout, Atlantic salmon [166, 168, 169]
TCR𝛼 Rainbow trout and Japanese flounder [170, 171]
TCR𝛽 Rainbow trout and Japanese flounder [170, 171]
TCRΥ Japanese flounder [171]
TCR𝜎 Japanese flounder [171]
CD28 Rainbow trout [47, 48]
CTLA Rainbow trout [47, 48]
CD40L Atlantic salmon and Japanese flounder [65, 172]
(3) T-cells
CD8𝛼 Rainbow trout, Atlantic salmon [51, 143, 173]
CD8𝛽 Atlantic salmon, Atlantic salmon [143, 169]
CD4 Atlantic salmon [169]
(4) Immunoglobulins
IgM Atlantic salmon, rainbow trout [56, 174, 175]
IgD Atlantic salmon, rainbow trout [59, 174]
IgT Rainbow trout, Atlantic salmon [58, 62]
IgZ Zebrafish [176]
also been characterized in fish [47, 48]. As for CD8 T-
cells, two subsets have been characterized, namely, CD8𝛼
and CD8𝛽, from different fish species of which CD8𝛼 has
been the most widely used marker for T-cell activation in
different studies [49–51].Moreover, cellmediated cytotoxicity
against allogeneic targets and virus infected cells has been
reported by different scientists [50, 52–54]. Put together
these observations suggest that fish T-cells possess surface
receptors essential for the binding to APCs comparable to
those found in mammals and that activation of T-cells into
effector cytotoxic T-lymphocytes (CTLs) could be based on
similar mechanisms to those seen in mammals.
There are three immunoglobulin isotypes characterized
in fish, this far, and these include IgM [55, 56] and IgD [55, 57]
also present inmammalswhile the recently identified IgT [58]
is only found in fish where it exists as membrane bound and
secreted form in serum [59, 60]. IgM is the most abundant
isotype in serumwhere it is estimated to be>1000-fold higher
than IgT [61, 62]. In addition, IgM has been detected in the
mucus of the skin, gills, and intestines although its levels in
these organs are far much lower than levels detected in serum
[61, 62]. On the contrary, IgT is predominantly found in the
mucus of the skin, gut, and intestines [61–63] where it is>100-
fold higher than levels detected in sera [61]. It is interesting to
note that the costimulatory marker CD40L mostly expressed
in activated CD4+T-cells, which binds to the CD40 receptors
on APCs in order to activate B-cell proliferation [64], has
been characterized in fish [65]. In addition, transcription
factors involved in specification of CD4 T-cells into different
T-helper (Th) subtypes have also been characterized, which
include T-bet [66, 67], GATA-3 [68–70], and ROR𝛾 [71, 72]
for the differentiation of naı¨ve CD4 T-cells into Th1, Th2,
andTh17 subtypes, respectively. In addition, several cytokines
linked to specification of CD4 T-cell into different subtypes
have been characterized and these include IL-2, IL-4, IL-
6, IL-10, IL-12, IFN𝛾, IL-15, IL-21, IL-22, and TGF𝛽 [40,
41, 73, 74]. Overall, the characterization of different APCs
and adaptive immune cells together with their receptors and
regulatory cytokine presented here suggests that teleosts fish
antigen presentation mechanisms could be comparable to
those used by mammals suggesting that antigen presentation
mechanisms have been conserved across the vertebrate taxa.
4 Journal of Immunology Research
MHC-II
MHC-I
TAPs
Nucleus
Endoplasmic reticulum
PeptidesProteosome
Viral proteins
Viral antigens
Presentation of
processed
antigens to the
cytotoxic
T-lymphocytes
(a)
Viral
peptides
Endosomal-lysosomal
compartment
Lysosome
MHC-II
MHC-I
TAPs
T-helper cells
Endosome
Viral antigen
Presentation of
processed
antigens to the
(b)
Figure 1: The endogenous and exogenous pathways of viral antigen entry into host cells. (a) Endogenous pathway shows viral antigens that
enter the host cells by the intracellular route. Once internalized, the viral antigens are degraded into peptides by proteasomes. Thereafter, the
processed antigenic peptides are transported via the transporter associated with antigen presentation (TAPs) to the endoplasmic reticulum
(ER) where they are loaded ontoMHC-Imolecules for presentation at the cell surface to CD8+T-cells. (b) Exogenous pathway shows antigens
that enter the antigen presenting cells (APCs) via the extracellular route which results in internalization of the antigens in the endosomes.
Thereafter, the endosomes fuse with the lysosomes to form the endosomal-lysosomal compartments that have MHC-II complexes. In the
endosomal-lysosomal compartments, the antigens are degraded into peptides followed by packaging of the peptides ontoMHC-II complexes.
Thereafter, the MHC-II complexes carrying the peptides are transported to the cell surface for presentation of the antigenic peptides to the
CD4 T-cells.
3. Intracellular Antigen Delivery Systems
Intracellular antigen delivery systems involve immunization
strategies that administer the vaccine antigens into the
cytoplasm (Figure 1) and these include the following.
3.1. Live Vaccines. Live vaccines use attenuated viruses or
recombinant antigens encoded by live virus vectors that
have the capacity to replicate in host cells with attenu-
ated pathogenicity lacking the ability to cause disease. As
analogues of pathogenic viruses, they engage with the cell
membrane by binding to surface receptors using epitopes
similar to their native virus, thereby gaining entry into
endosomal structures and the cytosol where they use the host
cell machinery to replicate. Consequently, the processed anti-
gens are presented on the cell surface by MHC-I molecules
while soluble antigens expressed by replicating virus are
engulfed by APCs to induce humoral immune responses
(Figure 1). Hence, live vaccines induce both cellular and
humoral immune responses.
In general, different scientists have reported the induction
of CTL responses in fish [52, 53, 75]. Utke et al. [76] showed
activation of the CTLs by viral hemorrhagic septicemia virus
(VHSV) infection in rainbow trout, while we [51] recently
showed activation of eomesodermin, a transcription factor
involved in activation of CD8𝛼 cells in Atlantic salmon
exposed to infectious pancreatic necrosis virus (IPNV).
Similarly, Chang et al. [49] showed activation of CD8𝛼 cells
after exposing orange spotted grouper (Epinephelus coioides)
to nervous necrosis virus (NNV). Flow cytometry analysis of
the spleen cells from fish exposed to NNV showed increased
mean fluorescent intensity of the CD8𝛼 cells and peripheral
blood leukocytes (PBLs) which were linked to increased
cytotoxicity andMHC-I restriction of the sorted lymphocytes
by recombinant CD8𝛼 antibodies. Several fish species have
shown upregulation of MHC-I and -II molecules [49, 77–80]
as well as expression of high antibody levels after exposure
to viral infections [81, 82] suggesting that attenuated viruses
administered as live vaccines could evoke both cellular and
humoral immunity. Based on these observations, several
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Table 2: Live vaccines.
Virus Abbreviation Fish host Mode of attenuation Protection Reference
Cyprinid herpesvirus subtype 3 CyHV-3 Carp Natural selection High [177]
Viral hemorrhagic septicemia
VHSV Rainbow trout Naturally attenuated High [178]
VHSV Rainbow trout Naturally attenuated High [84]
VHSV Olive flounder Recombinant (RG) modification High [179]
VHSV Rainbow trout Recombinant (RG) modification High [180]
VHSV Zebra fish Recombinant (RG) modification High [181]
Infectious hematopoietic necrosis virus
IHNV Rainbow trout Multiple serial passage High [86]
IHNV Rainbow trout Naturally attenuated High [83]
IHNV Rainbow trout Natural selection High [182]
IHNV Rainbow trout Recombinant (RG) modification High [91]
IHNV Rainbow trout Recombinant (RG) modification High [183]
Infectious pancreatic necrosis virus IPNV Atlantic salmon Avirulent strain/low dose High [82]
Rock bream iridovirus RSIV Rock bream Low temperature High [184]
attempts have been made to develop live viral vaccines for
fish (Table 2) and some of the strategies explored this far are
outlined below.
3.1.1. Natural Selection of Avirulent Strains. Roberti et al.
[83] discovered a naturally attenuated mutant of infectious
hematopoietic necrosis virus (IHNV) that conferred pro-
tection against IHNV in rainbow trout although the vac-
cine resulted in causing low level mortality after challenge.
Adelmann et al. [84] used an oral vaccine against VHSV
obtained from a naturally attenuated live virus selected using
monoclonal antibodies. In their study, they [84] showed
high expression levels of MHC-II and CD4 mRNAs. In
addition, they detected antibody responses that were linked
to significant protection in rainbow trout after challenge.
3.1.2. Attenuation by Serial Passages. An attenuated IHNV
vaccine was developed at Oregon State University bymultiple
passages using a rainbow trout isolate propagated using the
steelhead trout cell culture [85, 86]. The vaccine showed
high protection (95%) in vaccinated Chinook salmon while
mortality in control fish reached 90%. Although the vaccine
was highly protective in Chinook salmon, when used in
rainbow trout it showed significant mortality and as such
it was stopped [87, 88]. Since the Ab strain of infectious
pancreatic necrosis virus (IPNV)was found to be less virulent
than the West Buxton, Sp, or Jasper strain, Dorson et al.
[89] attempted to develop an attenuated strain of IPNV from
the Ab strain after several passages on RTG cells. Neither
the serially passaged nor the original Ab strain conferred
protection.
3.1.3. Reverse Genetics. Reverse genetics has been used in
fish vaccinology to generate avirulent strains for use as live
vaccines. For example, recombinant IHNV having a deletion
of the NV gene resulted in irreversible attenuation of the
wild type virulent strain resulting in the induction of high
protection levels in rainbow trout [90]. In another study,
recombinant IHNV generated by replacing the NV gene with
green fluorescent protein (GFP) or substituting the IHNV
G-gene with the G-gene of VHSV induced heterologous
protection in rainbow trout [91]. For IPNV, reverse genetics
was used to generate an avirulent strain for use as a live
vaccine against the wild type strain by substituting amino
acids on positions 217 and 221 of the VP2 capsid [92]. These
studies showed that the strain encoding the T
217
A
221
motif
caused high mortality in Atlantic salmon while the strain
encoding the P
217
T
221
motif was avirulent and linked to
subclinical infections [93]. Infecting Atlantic salmon with
high and low virulent strains at a nonpermissive physiological
state (presmoltification stage) did not result in mortality.
When the vaccinated fish were challenged at smolt stage
(permissive) the avirulent strain was less immunogenic than
the virulent vaccine strain [82]. In addition, we observed
that the avirulent strain reverted to virulence under stress
conditions [37, 94]. In general, the fear of reversion to
virulence has been the major hindrance for the licensure of
live vaccines in aquaculture.
3.2. DNAVaccines. The strategy of DNA vaccination is based
on the principle that the encoded immunogenic protein is
injected into the muscle or other tissues where it enters
the host cells and directs the synthesis of its polypeptide
antigen from the plasmid vector. Once transfected into host
cells, transcribed antigens replicate in the cytosol using the
endogenous pathway while soluble or secreted antigens are
phagocytized by APC and gain access into the exogenous
pathway (Figure 1). In principle, DNA vaccines result in the
in vivo synthesis of antigenic proteins using the host cell
machinery in a manner identical to natural virus infection
in the case of DNA vaccines made for viral diseases. This
culminates into antigenic proteins expressed by plasmid
DNA gaining access to both the exogenous and endogenous
pathways in the activation of both humoral and cellular
mediated immune responses.
Boudinot et al. [95] demonstrated the intracellular deliv-
ery of the plasmid DNA encoding the recombinant G protein
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Table 3: DNA vaccines explored in fish.
Classification Virus family Pathogen Abbreviation Antigen Protection∗ Reference
DNA viruses Iridovirus Red sea bream iridovirus RSIV Major capsid Moderate [185]
Herpesviridae Channel catfish virus (CCV) CCV ORF 6&59 Low [186]
RNA virus
Rhabdoviridae Viral hemorrhagic septicemia virus VHSV G High [95]
Rhabdoviridae Infectious hematopoietic necrosis virus IHNV G High [98, 187, 188]
Rhabdoviridae Spring viremia of carp virus SVCV G High [189, 190]
Rhabdoviridae Hirame rhabdovirus HRV G High [191]
Birnaviridae Infectious pancreatic necrosis virus IPNV SegA/VP2 Moderate [103, 140]
Orthomyxoviridae Infectious salmon anemia virus ISAV HE Moderate [192]
Togaviridae Salmon alphavirus subtype 3 SAV-3 E2 Moderate [157]
Nodaviridae Atlantic halibut nodavirus ANHV Capsid Low [193]
∗Protection was determined by postchallenge relative percent survival (RPS).
of VHSV inside the muscle cells of vaccinated rainbow trout.
Intracellular detection of the G-protein was shown up to 45
days at the injection sites. Transcription of the G-protein
was demonstrated by detection of mRNA in muscle tissue
extracts, which was linked to expression of high antibody
and MHC-II mRNAs levels. In another study, Utke et al.
[96] showed activation of the CTLs following immunization
using the G-protein of VHSV in rainbow trout. In their study,
they [96] used PBLs collected from fish immunized with a
DNA vaccine encoding the recombinant G -protein of VHSV
and showed that PBLs from vaccinated fish killed the VHSV
MHC-I matched RTG-2 cells indicating that the G-proteins
had the capacity to induce CTL responses in vaccinated
fish. They also showed the homing of leukocytes to the
injection site suggesting that cells expressing the recombinant
G-protein had a chemoattractant effect.This observation was
recently supported by Castro et al. [97] who showed that B-
lymphocytes, both IgM+ and IgT+ cells, represent one of the
major cell types infiltrating the injection sites expressing the
G-protein of VHSV. In their study, they showed upregulation
of CXCR3B, a receptor for CXCL11, together with CK5B
and CK6 chemokines, which could play chemotactic roles
in the early recruitment of B-cells at the injection sites. Put
together, these studies show that the intracellular expression
of proteins transcribed from DNA vaccines in fish cells
leads to homing of leukocytes and B-cells to injection sites
with possible involvements of chemoattractant chemokines.
Further, these studies suggest that antigens delivered by
this endogenous route evoke both the humoral and cellular
mediated immune responses in vaccinated fish.
Finally, it is important to point out that immunization
using DNA vaccines exhibits many advantages over the
live and inactivated vaccines. Intracellular synthesis of the
antigenic proteins poses no danger of reversion to virulence
and does not require inactivation of viruses using toxic
substances. High expression levels of humoral and cellular
responses can be achieved at low doses as shown byCorbeil et
al. [98] that nanogram quantities of a DNA vaccine protected
rainbow trout against IHNV infection after challenge. In
addition, intracellular synthesized antigens tend to fold in
their native conformation and correctly glycosylated display-
ing the neutralizing epitopes in a similar pattern to the native
virus [99]. In terms of genetic engineering, combinational
approaches can easily be adopted. For example, the use of
molecularly encoded cytokine adjuvants like IL-2 in DNA
engineered vaccines has shown the ability to enhance DNA
delivery and increase the duration and magnitude of plasmid
DNA expression in vivo [100]. Jimenez et al. [101] coinjected
recombinant IL-8 with plasmidDNA encoding the G-protein
of VHSV in rainbow trout and showed massive infiltration
of neutrophils at the injection site linked to upregulation of
proinflammatory cytokines. Table 3 shows the DNA vaccines
explored for use in fish, this far, of which only the DNA
vaccine for IHNV has been licensed in Canada (Novartis
Ltd.).
3.3. Fusion Protein Vaccines. This mode of antigen delivery
which has been referred to as “the first class ticket to
induction of MHC-I responses” relies on receptor mediated
internalization of viral antigens to the ER followed by
retrograde translocation into the cytosol [102]. Only a few
studies have explored this delivery system in fish vaccinology,
this far [103, 104]. Li-Li et al. [104] constructed a fusion
protein vaccine made by fusing the VP2-VP3 polyprotein
of IPNV with the exotoxin of Lactobacillus casei, which
resulted in reduced viral loads in vaccinated rainbow trout
after challenge while in our group we constructed a fusion
protein vaccine made by fusing the VP2 of IPNV with the
Pseudomonas aeruginosa exotoxin A (EP) [103]. The exact
mechanisms in which viral antigens are translocated into
the cytosol are dependent on three bacterial proteins as
illustrated from the PE fusion protein in Figure 2. The PE
protein has three functional domains, namely, the receptor
binding domain-I, transmembrane targeting domain-II, and
the toxic moiety domain-III. Domain-I binds to the 𝛼2-
macroglobulin receptor on the cell surface. After binding
to domain-I the ligand-receptor complex is internalized
through the receptor mediated endocytosis. After enzymatic
cleavage by the protease furin in the endosome, the protein
fragment encoding domains-II and -III is delivered into the
Golgi by the ER retrograde transport and further into the
cytosol using domain-II, which is responsible for transmem-
brane translocation of the toxin proteins into the cytoplasm.
Journal of Immunology Research 7
1∼252 253∼364 ∼404 405∼601
PE
(602 aa)
PJJ9 (ΔIII)
(425 aa)
PE-VP2-K3
(Δ1∼24, 165∼173)
(537 aa)
Aat II
VP2frag of IPNV
120 + 8 aa
VP2 (trunc) + KDEL3
IIIIa II Ib
Met +
Met +
1∼408
Poly His
Figure 2: The fusion of the VP2- of IPNV to the Pseudomonas aeruginosa exotoxin A (PE). PE shows a 602 aa exotoxin for Pseudomonas
aeruginosamade of three domains. Domain Ia (blue) located on 1–252 aa followed by domain II (green) on the location 253–364 aa, domain
Ib (blue) located on 365–404 aa, and finally domain III on the extreme end located on 405–601 aa. PJJ9 (ΔIII) is a 425 aa long intermediate
phase in which the toxic moiety of domain III has been cleaved. PE-VP2-KE is the final construct in which the toxic moiety of domain III
has been replaced with the truncated VP2 (yellow) immunogenic protein of infectious pancreatic necrosis virus (IPNV). Note that the VP2
is attached to the KDEL3 signaling peptide (red).
As shown in Figure 2, domain-III, which is toxic to cells, is
eliminated and is replaced with the immunogenic protein
(VP2) of IPNV bound to the KDEL signaling peptide. The
purpose of including the KDEL signaling peptide in the final
construct (PE-VP2-KDEL) is that it enables the binding of
the whole construct to the Golgi membrane KDEL-receptor.
Once bound to the Golgi membrane receptor, the ligand-
receptor complex is packaged into vesicles for retrograde
transport back to the ER where processed peptides are
packaged on MHC-I molecules for presentation on the cell
surface. In our studies, we employed the PE-VP2-KDEL
fusion protein to deliver the VP2 immunogenic protein of
IPNV intracellularly as a vaccine. Although we did not
assess the CTL responses induced by this antigen delivery
system, our findings show that these vaccines were able to
induce a low level antibody response suggesting that antigens
delivered using this method could gain access to induction
of humoral responses in vaccinated fish. However, there is
a need for detailed investigation to determine the role of
CTL responses induced by this mode of antigen delivery in
vaccinated fish.
3.4. Nanoparticle Vaccines. Polymeric nanoparticles for-
mulated from biodegradable polymers have been widely
explored as carriers for controlled delivery of vaccine antigens
[105, 106]. This system can potentially deliver antigens to
the desired location at predetermined rates and durations to
generate an optimal immune response [107]. For example,
Tian et al. [108–110] and Zheng et al. [111] showed that
lymphocytic disease virus (LCDV) encapsulated in particles
sustained a much longer release of the DNA antigen than
naked DNA injected in Japanese flounder. In addition,
carriers protect the antigen from degradation until release as
shown by Rajeshkumar et al. [112] that encapsulated DNA
antigens were protected from degradation by DNAase for
vaccines used in the Asian sea bass (Lates calcarifer).
To deliver the antigens into host cells, nanoparticle
materials are internalized by endocytosis [113]. To deliver
the antigens into the cytosol, the release of antigens from
the acidic endosomes requires membrane disruptive agents,
which release the internalized proteins into the cytosol.
Therefore, encapsulation carriers should include membrane
penetrating peptides and polymers that disrupt the mem-
branes when the pH declines in the endosomes. For example,
Standley et al. [114] made acid degradable nanoparticles,
which were designed to release encapsulated proteins in a
pH-dependent manner. In their study, they made nanopar-
ticles that were stable at pH 7.4 but quickly degradable at
pH 5.0 in the acidic endosomal environment enabling the
release of antigens into the cytosol, ultimately resulting in
upregulation of MHC-I. Another method explored is the
use of amphiphilic polymers [115–117], which also have pH-
dependent membrane disruptive properties protonated at
the endosomal pH range [115, 118]. Upon reduction of the
endosomal pH, these particles increase their hydrophobicity
to facilitate the disruption and penetration of the endosomal
membranes culminating in the release of antigens in the
cytosol. These amphiphilic polymers have been shown to
increase CD8+ responses and to improve vaccine potency
[119]. In summary, these studies show that nanoparticle
antigen delivery systems can be designed to deliver antigens
through the intra- or extracellular routes to evoke immune
responses linked to the MHC-I or -II pathways.
Studies in higher vertebrates have shown that APCs easily
carry out phagocytosis of nanoparticles and microparticles
between 150 nmand4.5 𝜇m[120, 121]with the optimal size for
phagocytosis being 500 nm [122] while monocytes have been
shown to easily phagocytose nanoparticles >100 nm [123].
And, as pointed out byGutierro et al. [124], nanoparticles that
encapsulate antigens resemble pathogens in terms of their
uptake into host cells by mirroring the route of pathogen
uptake and the immune response triggered after nanoparticle
uptake. Fehr et al. [125] and He et al. [120] have also
pointed out that nanoparticles can also be used to carry
antigens on their surface which would serve as a good
stimulant for the induction of B-cell responses. Although
antigen delivery using nanoparticle vaccines has been well
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Table 4: Nanoparticle vaccines.
Virus Virus Fish host Admin Antigen Type Protection∗ Reference
Lymphocytic virus LCDV Japanese flounder Oral Plasmid DNA PLGA High [194]
Infectious hematopoietic necrosis virus IHNV Rainbow trout Oral Plasmid DNA PLGA Low [195]
Infectious pancreatic necrosis virus IPNV Atlantic salmon Injection IWV PLGA Low [127]
Infectious pancreatic necrosis virus IPNV Atlantic salmon Injection IWV PLGA Low [103]
White syndromes spot virus WSSV Shrimp Oral Plasmid DNA Chitosan ND [112]
White syndromes spot virus WSSV Shrimp Oral Plasmid DNA Chitosan ND [196]
∗Protection was determined by postchallenge relative percent survival (RPS). ND = not done (not tested for protection).
studied in higher vertebrates, indications are that fish cells
use similar mechanisms of antigen uptake from nanoparticle
based vaccines. For example, Ruyra et al. [126] showed entry
of liposome-based nanoparticles in zebrafish hepatocytes and
trout macrophages by endocytosis. Upon entry, the nanopar-
ticle laden cells initiated specific proinflammatory responses
while Fredriksen and Grip [127] showed intracellular cyto-
plasmic localization of polylactic-coglycolic acid (PLGA)
nanoparticles in TO-cells [24].These findings support earlier
observations, which showed that because PLGA particles are
less hydrophilic than alginates, they are easily incorporated
into host cells, which makes them suitable vehicles for
delivering antigens into intracellular compartments [128–
131]. Recently, we [103] used PLGA nanoparticles to deliver
inactivated whole viral particles of IPNV as a vaccine, which
expressed low antibody levels comparable to those induced
by inactivated whole virus (IWV) vaccines suggesting that
delivery of antigens using PLGA nanoparticles has the
ability to induce humoral immune responses in vaccinated
fish. Although there are limited studies that categorically
demonstrate the intracellular delivery of nanoparticle based
vaccines in fish cells, Rajeshkumar et al. [112] were able to
induce low level cytotoxicity (tested in vitro) using chitosan
nanoparticle vaccines in Asian sea bass vaccinated against
vibriosis (Listonella anguillarum). Table 4 shows that only
a few studies have been carried out using nanoparticle
based technologies to administer viral antigens in fish. In
general, indications show that nanoparticle based vaccines
have the potential to deliver antigens into different host cell
compartments and thus that they can induce cellular and
humoral immune responses in vaccinated fish. The efficacy
of nanoparticle vaccines needs to be improved and explored
in more detail.
4. Extracellular Antigen Delivery Systems
This approach involves antigen delivery systems that admin-
ister viral antigens into the extracellular compartments using
the exogenous pathway (Figure 1).
4.1. Inactivated Whole Viral Vaccines. This mode of antigen
delivery ensures that the antigenic protein is preserved in its
native structure while the virus is rendered nonreplicative
using chemical or physical methods. Given that inactivated
whole virus (IWV) vaccines are nonreplicative, it follows
that their antigens enter the host cells by the exogenous
route and their processed peptides are presented to CD4
cells via the MHC-II pathway. And, as such, several studies
have shown upregulation of MHC-II genes in response to
vaccination using IWV vaccines [77, 132]. In terms of CD4
T-cell differentiation, IWV vaccines have been shown to
predominantly activate genes linked to the T-helper 2 (Th2)
responses [133]. For example, we showed upregulation of
GATA-3, a transcription factor linked to activation of na¨ıve
CD4 cells intoTh2 responses, when genes linked to activation
of Th1 and CD8 T-cell responses were downregulated [51].
In this study, we showed a high correlation between GATA-
3 and antibody levels expressed against IPNV [51]. In terms
of antibody responses, IWV vaccines [134] have been linked
to high expression levels of IgM and IgT in vaccinated
fish [135]. In our studies, we showed a high correlation
between postchallenge reduction of mortality and systemic
IgM levels, suggesting IgM levels could serve as a correlate
of protection for IWV vaccines [81]. Overall, these studies
strongly suggest that IWV vaccines are to be considered
as exogenous antigens, mainly inducing humoral immune
responses. Table 5 shows the major IWV vaccines explored
in fish vaccinology this far.
4.2. Subunit Vaccines. Thebasic principle for this vaccination
strategy is that the gene encoding the antigenic proteins
is isolated from the native virus and transferred into a
heterologous vector that is nonpathogenic for propagation.
Table 6 shows the antigenic proteins identified for the major
fish viral diseases and the different expression vectors used
for propagation. In the case of VHSV and IHNV, production
of subunit vaccines has focused on cloning the G-protein
into heterologous vectors [136–138] while, for viruses such
as IPNV, the strategy has been to clone the entire outer
capsid encoding the protective epitopes, instead of protein
segments coding the neutralizing epitopes in heterologous
vectors [103, 139–141]. Subunit vaccines are nonreplicative
and are delivered exogenously to host cells by the extra-
cellular route (Figure 1). Similar to IWV vaccines, subunit
vaccines induce humoral immune responses and upregula-
tion of MHC-II genes [139, 142], which is consistent with
observations in higher vertebrates in which it has been
shown that immune responses induced by subunit vaccines
are mainly dependent on the MHC-II pathway and that
they elicit antibody responses [143]. Øverga˚rd et al. [144,
145] showed a high correlation between reduction of viral
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Table 5: Inactivated whole virus vaccines explored in fish.
Pathogen Abbreviation Virus family Fish species Protection Reference
Viral hemorrhagic septicemia virus VHSV Rhabdoviridae Rainbow trout High∗ [197]
Infectious hematopoietic necrosis virus IHNV Rhabdoviridae Rainbow trout High∗ [198]
Spring viremia of carp virus SVCV Rhabdoviridae Carp High∗ [199]
Infectious pancreatic necrosis virus IPNV Birnaviridae Atlantic salmon High∗ [81, 103]
Salmon pancreas disease virus SPDV Togaviridae Rainbow trout High2 [200]
Red seabream iridovirus RSIV Iridovirus Sea bass High∗ [201]
Singapore grouper iridovirus SGIV Iridovirus Grouper High∗ [202]
Channel catfish virus CCV Herpesviridae Catfish Moderate/high∗ [203]
Cyprinid herpesvirus subtype-3 CyHV-3 Herpesviridae Carp High∗ [204]
Nervous necrosis virus NNV Betanodaviridae Grouper High1 [205]
Nervous necrosis virus NNV Betanodaviridae Sea bass High1 [206]
Salmon anemia virus SAV Orthomyxoviridae Atlantic salmon High∗ [207]
Protection measured by ∗relative percent survival (RPS), 1protection against postchallenge virus infection, and 2pathology.
Table 6: Subunit vaccines.
Virus Abbreviation Protein Vector Efficacy Fish species Reference
Infectious pancreatic necrosis virus
IPNV VP2 Escherichia coli Low Atlantic salmon [103]
IPNV VP2 Yeast cells Low Rainbow trout [139]
IPNV VP2/3 Lactobacillus casei Low Rainbow trout [208]
IPNV VP2 Baculovirus Low Atlantic salmon [141]
IPNV VP2 Semliki Forest virus N/A CHSE cells [209]
Viral hemorrhagic septicemia virus
VHSV G Saccharomyces cerevisiae — Rainbow trout [210]
VHSV G Escherichia coli High Rainbow trout [197]
VHSV G Yersinia ruckeri Moderate-high Rainbow trout [211]
VHSV G Baculovirus high Rainbow trout [142]
VHSV G Edwardsiella tarda Moderate Olive flounder [212]
Infectious hematopoietic necrosis virus
IHNV G Escherichia coli Moderate Rainbow trout [138]
IHNV G Caulobacter crescentus Low Rainbow trout [213]
IHNV G Baculovirus Moderate Rainbow trout [214]
IHNV G Aeromonas salmonicida Moderate-high Rainbow trout [137]
GCRV VP4 Escherichia coli Moderate-high Grass carp [215]
GCRV VP5, VP7 Escherichia coli Moderate Grass carp [216]
VER Capsid Escherichia coli Low Atlantic halibut [217]
RNA and activation of CD4 markers in Atlantic halibut
(Hippoglossus hippoglossus L.) immunized using a subunit
vaccine for nodavirus. Although cross presentation of exoge-
nously processed peptides from endosomes into the cytosol
has been reported in higher vertebrates [3, 4], there is no
study demonstrating cross presentation of peptides processed
from endosomes into the cytosol for subunit vaccines in
fish.
4.3. Virus-Like and Subviral Particle Vaccines. Structural
proteins of most viruses self-assemble to forms capsids in
different expression systems that resemble the native virus
structure in size and morphology and, hence, they are
referred to as “virus-like particles” (VLPs). For example, Liu
et al. [146] made VLPs of nodavirus expressed in E. coli or
Spodoptera frugiperda (Sf21) insect cells that formed small,
nonenveloped 𝑇 = 3 quasi-symmetric particles [147, 148].
They showed that the capsid ofmalabaricus grouper nervous
necrosis virus (MGNNV) spontaneously self-assembled into
VLPs when expressed in Sf21 cells infected with a recombi-
nant baculovirus [148]. These VLPs were indistinguishable
from the native virus particles by electron microscopy and
the 3D structure of the VLPs was resolved at 2.3 nm by
cryomicroscopy [147]. Similarly, Fang et al. [149] produced
VLPs that were devoid of the nucleoprotein but resembled
the outer capsid of the native grass carp reovirus (GCRV).
However, in some cases VLPs are formed from replication
of surface particulate components that do not form the
entire capsid, but they contain elements of the outer capsid
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Table 7: Subviral, immature, and virus-like particles used for fish vaccines.
Virus Classification Protein Cells/vector Fish host Protection Reference
NNV VLP Capsid Escherichia coli Orange spotted grouper ND∗ [153]
NNV VLP Capsid Saccharomyces cerevisiae Red spotted grouper ND∗ [218]
IPNV VLP VP2 Baculovirus/insect larvae Rainbow trout Low [219]
IPNV IVP VP2 CHSE cells Rainbow trout ND∗ [151]
IPNV SVP VP2 Yeast cells Rainbow trout Low [150]
IPNV SVP VP2 Yeast cells Rainbow trout Low [139]
GCRV SVP Capsid Ctenopharyngodon idellus Grass carp ND∗ [149, 220]
VNNV VLP Capsid Baculovirus European sea bass High [221]
NNV VLP Capsid Baculovirus Orange spotted grouper High [148]
NNV VLP Capsid Escherichia coli Dragon and Malabar grouper ND∗ [146]
VHSV Peptide Nucleoprotein Rainbow trout ND∗ [136]
ND = Note done (No protection studies carried out).
∗Only immune expression studies were carried out by enzyme linked immunosorbent assay (ELISA) or gene expression.
that are immunogenic. These protein structures are called
“subviral particles” (SVPs). Both VLPs and SVPs do not
contain the nucleoprotein and as such they are nonreplicative.
Table 7 shows the VLPs, SVPs, and immature virus particles
(IVPs) made from different fish viruses. As shown in Table 7,
different expression systems were used to make VLPs [139],
SVPs [150], and IVPs [151] for IPNV.
Given the similarity to their native viral capsids, VLPs
provide an excellent platform for displaying viral epitopes
[146, 152]. This property was demonstrated by Lai et al. [153]
who producedVLPs forNNV expressed in E. coli and showed
that NNV failed to infect the Asian sea bass cells that were
exposed to the VLPs prior to infection, suggesting that the
cell surface receptors were occupied by the VLP-epitopes
blocking the wild type virus from entering the cells and
thereby protected the cells from developing cytopathic effect
(CPE) while control cells not exposed to VLPs developed full
CPE. Liu et al. [146] showed that VLPs generated from NNV
induced high antibody responses that lasted for more than
five months, similar to those produced by the native wild
type virus, which were correlated with long-term protection
in vaccinated orange spotted grouper. Similarly, Lai et al.
[153] produced VLPs in E. coli for NNV that expressed high
antibody levels, which were correlated with IgM, MHC-II,
and CD4 levels in vaccinated fish.These observations suggest
VLPs induce the expression of CD4 responses through the
MHC-II pathways in a similar pattern to those induced by
subunit vaccines in Mammalia [154].
5. General Discussion and Conclusion
Themost explored strategies for the delivery of antigens using
the intracellular route in fish vaccinology involve the use of
live and DNA vaccines. The use of DNA vaccines in fish
has undergone intense investigation in the last decades as a
substitute of replicative antigens for live vaccines. Although
factors leading to higher performance of DNA vaccines for
rhabdoviruses compared to other fish viral families have
not been elucidated, similar observations seen in higher
vertebrates show that DNA vaccines for rhabdoviruses are
more protective [155, 156] than some of the DNA vaccines for
other viral families. In general, replicative vaccines delivered
via the intracellular route have been linked to activation
of cellular and humoral immune responses in vaccinated
fish, which makes these vaccines be more protective than
nonreplicative vaccines delivered by the extracellular route.
For antigens administered by the extracellular route,
several antigen delivery strategies have been explored in fish
vaccinology, which include the use of IWV, subunit, SVP,
VLP, and IMP vaccines. In general, all exogenous antigens
induce humoral immune responses. In terms of cellular
immunity, exogenous antigens were linked to expression of
MHC-II and CD4 genes. However, new innovations such
as the use of fusion protein and nanoparticles vaccines
having the potential to deliver nonreplicative antigens into
the cytosol are likely to induce CTL responses in vaccinated
fish. The use of nanoparticle vaccines has attracted a lot of
interest in the delivery of oral vaccines for fish production
systems that require a boost vaccination when fish have been
transferred in cages to the sea after prime immunization
using parenteral vaccines at the freshwater stage. In general,
IWVvaccines are superior to subunit vaccines given that they
produce high antibody levels, which correlate with protection
in vaccinated fish [81, 157]. In addition, these vaccines have
been shown to activate the expression of CD4 andTh2 genes
that correlate with high antibody levels consolidating the
common notion that exogenous antigens stimulate humoral
immune responses orchestrated byTh2 cytokines [154].
Although we did not review the role of APC prime/
activated B-cells in antigen uptake and presentation to cells
of the adaptive immune system in detail given the limited
studies carried out on this topic in fish vaccinology, we can
conclude that the different antigen delivery systems explored
in fish this far deliver their antigens into the intra- and
extracellular compartments and that they activate either the
cellular or humoral immune response or both depending on
the route of antigen delivery. As pointed out by Howarth
and Elliot [158], the most protective vaccines are those that
stimulate both the CD4+ and CD8+ T-cells responses and,
as such, replicative vaccines such as the live and DNA
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Table 8: Comparison of the intra- and extracellular antigen processing parameters.
Parameters Intracellular antigen delivery Extracellular antigen delivery
Vaccine types
Viability of antigens Mostly replicative Nonreplicative
Examples of vaccine types Live and DNA vaccines IWV vaccines, subunit vaccines
Antigen uptake and presentation
Pathway of uptake into host cells Endogenous pathway Exogenous pathway
Antigen uptake and processing Penetration of host cell membrane Phagocytosis by APCs
Site of antigen deposition Cytoplasm Endosome/phagosome
Antigen presenting molecules MHC-I and MHC-II MHC-II
Mode of antigen processing Proteosomal degradation Endosomal degradation
Adaptive immunity
Type of immune response induced Cellular and humoral immune responses Humoral immune responses
Cell types involved B- and T-lymphocytes B-lymphocytes
T-cell subtypes CD4 and CD8 T-cells CD4 T-cells
Effector molecules/cells CTL (cellular) and antibodies (humoral) Antibodies
Effector mechanisms CTL killing of virus infected cells Antibody-neutralization of virus
Antibody-neutralization of virus
vaccines that stimulate both the MHC-I and -II pathways
are likely to produce better protection in fish (Table 8).
So far only the IHNV-DNA vaccine for use in Atlantic
salmon in Canada is the only one licensed while live viral
vaccines are feared to revert to virulence. Hence, the use
of IWV vaccines which accounts for the largest proportion
of licensed vaccines is likely to continue dominating the
vaccine industry in aquaculture [81, 157]. Therefore, the
search for better antigen delivery systems that stimulate
both CD4+ and CD8+ responses that have the potential
to induce long-lasting protective immunity has to continue.
Overall, we anticipate that the synopsis of different antigen
delivery systems presented here will shed new insights into
the limitations and successes of the current immunization
strategies used in fish vaccinology.
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